---
schema_version: "secwatch.filing_event.v1"
accession: "0001448431-25-000010"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:22:20.942449+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q2 revenue $29.2M (+55% YoY); raises FY guidance to $104M-$108M

## Summary
- Q2 GAAP net income $1.5M ($0.08/share) vs net loss of $4.0M ($0.22) YoY.
- Adjusted EBITDA $5.8M vs $0.5M YoY; non-GAAP net income $4.5M ($0.24 diluted).
- Q2 gross profit $18.6M, up 59% YoY; revenue growth driven by deeper pharma partnerships.
- Paid down $4.5M of principal on term loan during Q2, $4.0M above required schedule.
- FY 2025 guidance raised: revenue $104M-$108M, adjusted EBITDA $14.5M-$17.5M.

## SEC filing metadata
- accession: 0001448431-25-000010
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000144843125000010/0001448431-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000144843125000010/oprx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001448431-25-000010
- JSON: https://secwatch.observer/filing/0001448431-25-000010.json
- Plain text: https://secwatch.observer/filing/0001448431-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.